A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Lipidic Aminoglycoside Derivatives: A New Class of Immunomodulators Inducing a Potent Innate Immune Stimulation
Development of simple and fully characterized immunomodulatory molecules is an active area of research to enhance current immunotherapies. Monophosphoryl lipid A (MPL), a nontoxic lipidic derivative from bacteria, is the first and currently only adjuvant approved in humans. However, its capacity to induce a potent response against weak immunogenic tumoral‐associated antigens remains limited. Herein, a new generation of lipidic immunomodulators to conduct a structure–activity relationship study to determine the minimal structural elements conferring immunomodulatory properties is introduced. Two lead molecules characterized by a short succinyl linker between two oleyl chains and a polar headgroup consisting of either naturally occurring tobramycin (DOST) or kanamycin (DOSK) are identified. These two lipoaminoglycosides self‐assemble in very small vesicles. In a wide variety of cells including 3D human cell culture, DOST and DOSK induce the upregulation of proinflammatory cytokines and interferon‐inducible proteins in a dose and time‐dependent manner via a caveolae‐dependent proinflammatory mechanism and phosphatidylinositol phospholipase C activation. Furthermore, after intratumoral administration, these lipoaminoglycosides induce an efficient immune response leading to significant antitumor activity in a mouse breast cancer model. Altogether, these findings indicate that DOST and DOSK are two groundbreaking synthetic lipid immunostimulators that can be used as adjuvants to enhance current immunotherapeutic treatments.
Lipidic Aminoglycoside Derivatives: A New Class of Immunomodulators Inducing a Potent Innate Immune Stimulation
Development of simple and fully characterized immunomodulatory molecules is an active area of research to enhance current immunotherapies. Monophosphoryl lipid A (MPL), a nontoxic lipidic derivative from bacteria, is the first and currently only adjuvant approved in humans. However, its capacity to induce a potent response against weak immunogenic tumoral‐associated antigens remains limited. Herein, a new generation of lipidic immunomodulators to conduct a structure–activity relationship study to determine the minimal structural elements conferring immunomodulatory properties is introduced. Two lead molecules characterized by a short succinyl linker between two oleyl chains and a polar headgroup consisting of either naturally occurring tobramycin (DOST) or kanamycin (DOSK) are identified. These two lipoaminoglycosides self‐assemble in very small vesicles. In a wide variety of cells including 3D human cell culture, DOST and DOSK induce the upregulation of proinflammatory cytokines and interferon‐inducible proteins in a dose and time‐dependent manner via a caveolae‐dependent proinflammatory mechanism and phosphatidylinositol phospholipase C activation. Furthermore, after intratumoral administration, these lipoaminoglycosides induce an efficient immune response leading to significant antitumor activity in a mouse breast cancer model. Altogether, these findings indicate that DOST and DOSK are two groundbreaking synthetic lipid immunostimulators that can be used as adjuvants to enhance current immunotherapeutic treatments.
Lipidic Aminoglycoside Derivatives: A New Class of Immunomodulators Inducing a Potent Innate Immune Stimulation
Colombani, Thibault (author) / Haudebourg, Thomas (author) / Decossas, Marion (author) / Lambert, Olivier (author) / Ada Da Silva, Grace (author) / Altare, Frederic (author) / Pitard, Bruno (author)
Advanced Science ; 6
2019-08-01
13 pages
Article (Journal)
Electronic Resource
English
Lipid-Modified Aminoglycoside Derivatives for In Vivo siRNA Delivery
| British Library Online Contents | 2013
Mitochondrial dynamics and the innate antiviral immune response
| British Library Online Contents | 2014
Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer
| Wiley | 2024
Biology of Longevity: Role of the Innate Immune System
| British Library Online Contents | 2006